Contact
searchSearch
HMP Global
Login
Test Your Knowledge

Quiz: Do BMI and ER Status Impact Outcomes in Breast Cancer?

07/29/2020

Recent News

News
Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with durvalumab plus anlotinib improved progression-free survival compared with durvalumab alone in patients with extensive-stage small cell lung cancer following first-line chemoimmunotherapy, according to results from...
Maintenance therapy with...
07/02/2026
Oncology
News
Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Updated findings from the ASTRUM-005 trial showed that adding serplulimab to carboplatin and etoposide continued to improve long-term survival in patients with previously untreated extensive-stage small cell lung cancer.
Updated findings from the ASTRUM-005 trial showed that adding serplulimab to carboplatin and etoposide continued to improve long-term survival in patients with previously untreated extensive-stage small cell lung cancer.
Updated findings from the...
07/02/2026
Oncology
News
Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer
07/02/2026
Emily Estrada
Real-world data from a large retrospective cohort study demonstrated that first-line chemoimmunotherapy significantly improved survival in patients with extensive-stage small cell lung cancer.
Real-world data from a large retrospective cohort study demonstrated that first-line chemoimmunotherapy significantly improved survival in patients with extensive-stage small cell lung cancer.
Real-world data from a large...
07/02/2026
Oncology
FDA Approval
FDA Approves BESREMi Pen, Expanding Self-Administration Options for Patients With Polycythemia Vera
07/01/2026
Emily Estrada
The FDA has approved the BESREMi Pen, a prefilled ropeginterferon alfa-2b-njft delivery device, for adults with polycythemia vera, providing a new option designed to simplify self-administration of chronic interferon therapy.
The FDA has approved the BESREMi Pen, a prefilled ropeginterferon alfa-2b-njft delivery device, for adults with polycythemia vera, providing a new option designed to simplify self-administration of chronic interferon therapy.
The FDA has approved the BESREMi...
07/01/2026
Oncology
News
MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma
06/30/2026
Emily Estrada
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.
Results from the phase 2 UNITED...
06/30/2026
Oncology
News
WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas
06/30/2026
Emily Estrada
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.
Results from a phase 1/2 study...
06/30/2026
Oncology
News
Venetoclax-Based Conditioning Regimen Prior to Allo-HSCT for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
06/30/2026
Emily Estrada
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial...
06/30/2026
Oncology
News
Navitoclax Plus Venetoclax and Decitabine Shows Early Activity in High-Risk Myeloid Malignancies
06/30/2026
Emily Estrada
Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.
Results from a phase 1 study demonstrated that the addition of navitoclax to venetoclax plus decitabine was safe and showed encouraging preliminary activity among patients with high-risk myeloid malignancies.
Results from a phase 1 study...
06/30/2026
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use